Verition Fund Management’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.99M | Buy |
+3,675
| New | +$2.07M | 0.01% | 1110 |
|
|
2026
Q1 | – | Sell |
-15,029
| Closed | -$7.32M | – | 3583 |
|
|
2025
Q4 | $7.32M | Sell |
15,029
-1,573
| -9% | -$733K | 0.03% | 624 |
|
|
2025
Q3 | $6.96M | Sell |
16,602
-2,579
| -13% | -$867K | 0.03% | 814 |
|
|
2025
Q2 | $5.51M | Buy |
19,181
+17,168
| +853% | +$5.13M | 0.02% | 1007 |
|
|
2025
Q1 | $621K | Sell |
2,013
-4,050
| -67% | -$1.39M | ﹤0.01% | 2438 |
|
|
2024
Q4 | $2.14M | Buy |
+6,063
| New | +$2.23M | 0.01% | 1506 |
|
|
2024
Q3 | – | Sell |
-2,693
| Closed | -$858K | – | 3525 |
|
|
2024
Q2 | $858K | Buy |
2,693
+420
| +18% | +$111K | ﹤0.01% | 1763 |
|
|
2024
Q1 | $522K | Sell |
2,273
-3,718
| -62% | -$839K | ﹤0.01% | 1984 |
|
|
2023
Q4 | $1.32M | Buy |
5,991
+1,512
| +34% | +$349K | 0.01% | 1040 |
|
|
2023
Q3 | $1.01M | Sell |
4,479
-3,457
| -44% | -$796K | 0.01% | 1075 |
|
|
2023
Q2 | $1.75M | Buy |
7,936
+6,978
| +728% | +$1.55M | 0.02% | 730 |
|
|
2023
Q1 | $215K | Sell |
958
-3,085
| -76% | -$761K | ﹤0.01% | 1726 |
|
|
2022
Q4 | $1.12M | Buy |
4,043
+2,217
| +121% | +$560K | 0.02% | 862 |
|
|
2022
Q3 | $382K | Buy |
1,826
+603
| +49% | +$135K | ﹤0.01% | 2065 |
|
|
2022
Q2 | $288K | Buy |
+1,223
| New | +$249K | 0.01% | 1748 |
|
|
2021
Q4 | – | Sell |
-1,843
| Closed | -$340K | – | 2816 |
|
|
2021
Q3 | $340K | Buy |
1,843
+660
| +56% | +$130K | ﹤0.01% | 1414 |
|
|
2021
Q2 | $212K | Buy |
+1,183
| New | +$225K | ﹤0.01% | 1554 |
|
|
2020
Q3 | – | Sell |
-3,534
| Closed | -$428K | – | 1383 |
|
|
2020
Q2 | $428K | Buy |
+3,534
| New | +$398K | 0.01% | 658 |
|
|
2020
Q1 | – | Sell |
-4,237
| Closed | -$373K | – | 1070 |
|
|
2019
Q4 | $373K | Sell |
4,237
-2,163
| -34% | -$190K | 0.01% | 772 |
|
|
2019
Q3 | $510K | Buy |
6,400
+580
| +10% | +$46.7K | 0.01% | 619 |
|
|
2019
Q2 | $454K | Buy |
+5,820
| New | +$544K | 0.01% | 701 |
|
|
2016
Q3 | – | Sell |
-4,768
| Closed | -$505K | – | 1319 |
|
|
2016
Q2 | $505K | Buy |
4,768
+1,095
| +30% | +$122K | 0.06% | 381 |
|
|
2016
Q1 | $409K | Sell |
3,673
-4,288
| -54% | -$543K | 0.07% | 376 |
|
|
2015
Q4 | $1.25M | Buy |
+7,961
| New | +$1.16M | 0.24% | 83 |
|
|
2015
Q2 | – | Sell |
-3,399
| Closed | -$586K | – | 721 |
|
|
2015
Q1 | $586K | Buy |
+3,399
| New | +$518K | 0.07% | 88 |
|
|
2014
Q4 | – | Sell |
-3,854
| Closed | -$496K | – | 662 |
|
|
2014
Q3 | $496K | Buy |
+3,854
| New | +$397K | 0.07% | 241 |
|
Other funds holding UTHR
ACA
JT
Verition Fund Management's UTHR Position: Q2 2026 in Review
Verition Fund Management opened a new position in United Therapeutics (UTHR) in Q2 2026: 3,675 shares worth $1.99M. The stake represents 0.01% of the portfolio and ranks #1110 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in UTHR as recently as Q4 2025.
Verition Fund Management first reported a position in UTHR in Q3 2014 and has held it in 26 quarters since. The position peaked at $7.32M in Q4 2025. 875 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.
- Verition Fund Management held 3,675 shares of United Therapeutics worth $1.99M as of Q2 2026.
- United Therapeutics was a new Verition Fund Management position in Q2 2026.
- United Therapeutics made up 0.01% of Verition Fund Management's portfolio in Q2 2026, its #1110 holding.
- Verition Fund Management first reported a position in United Therapeutics in Q3 2014 and has held it in 26 quarters since.
- Verition Fund Management's United Therapeutics position peaked at $7.32M in Q4 2025.
- 875 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.
Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.